Triple-negative breast cancer carries one of oncology's bleakest prognoses precisely because it lacks the hormone receptor and HER2 targets that modern therapies exploit. For the subset of TNBC patients who cannot receive immunotherapy — due to autoimmune conditions, prior immune-related toxicities, or PD-L1-negative tumors — first-line options have historically been limited to conventional chemotherapy with modest outcomes. A large randomized trial now challenges that therapeutic ceiling.
The TROPION-Breast02 phase III trial enrolled 644 patients with previously untreated, locally recurrent inoperable or metastatic TNBC who were ineligible for immunotherapy, randomizing them 1:1 to datopotamab deruxtecan (Dato-DXd, an antibody-drug conjugate targeting TROP2 at 6 mg/kg every three weeks) or investigator's choice of chemotherapy. Dato-DXd produced a median progression-free survival of 10.8 months versus 5.6 months with chemotherapy — a hazard ratio of 0.57, translating to a 43% relative reduction in progression or death risk. Overall survival also improved significantly: 23.7 months versus 18.7 months, with a hazard ratio of 0.79.
Dato-DXd belongs to the antibody-drug conjugate class that has reshaped solid tumor oncology over the past half-decade. Its TROP2-targeting mechanism is distinct from sacituzumab govitecan, another TROP2-directed ADC already approved in TNBC, raising important questions about sequencing and potential cross-resistance. Critically, this trial specifically addressed the immunotherapy-ineligible population — a group that has been consistently underrepresented in recent TNBC trials dominated by PD-L1 biomarker selection. The five-month overall survival gain is clinically meaningful in a disease where historical median OS rarely exceeded 15–18 months in comparable populations. Key limitations include the open-label design, which can influence supportive care decisions, and the generalizability question of how findings translate across the geographic strata enrolled. This trial is best characterized as paradigm-shifting for a neglected TNBC subpopulation, and likely to accelerate regulatory review for a first-line indication.